PF 06755347

Drug Profile

PF 06755347

Alternative Names: PF-06755347

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic inflammatory demyelinating polyradiculoneuropathy

Most Recent Events

  • 05 Sep 2017 Pfizer suspends phase I trial in Chronic inflammatory demyelinating polyradiculoneuropathy (In volunteers) in USA for protocol amendment (NCT03275740)
  • 17 Jul 2017 Phase-I clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy (In volunteers) in USA (IV) (NCT03275740)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top